Testing safety of a nose spray for staph bacteria
Part of Infections clinical trials.
This trial tests a new nose spray called HY-133 to see if it's safe and can clear a common type of staph bacteria from the nose. It is for people who have this bacteria but not the antibiotic-resistant kind.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a certain type of staph bacteria (MSSA) in your nose, not the resistant type (MRSA).
- You must not have any major health problems like diabetes or heart disease.
- You must not have a runny nose from allergies or other causes.
- You must not have used antibiotics or any nose treatment in the last 12 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether dupilumab (an injection) can reduce staph bacteria in the nose and make the nose’s microbes more diverse in adults with chronic rhinosinusitis with nasal polyps (CRSwNP). If you already have a plan to start dupilumab as standard care, the study may help doctors better understand why it works.
This trial tests a special nasal spray gel that combines stem cell exosomes, an antibiotic, and an enzyme to treat chronic sinusitis caused by staph bacteria. It aims to reduce infection and improve symptoms like nasal blockage and discharge.
This trial tests a new nasal spray (called LMN-1001) in healthy adults to see if it is safe and how the body handles it. It is an early-phase study, so the main goal is not to treat a disease but to check for safety and side effects.
This study tests whether giving a nasal spray of healthy bacteria to infants can restore good germs in the nose after they receive mupirocin ointment to treat Staph aureus. It aims to bring back a healthy nasal microbiome.
This trial tests a nasal spray called VVN432 in healthy volunteers and people with chronic sinusitis. It checks if the spray is safe and how the body processes it.
This trial tests if an investigational nasal spray (ETH47) can reduce asthma symptoms triggered by a common cold virus (rhinovirus). You will be exposed to the virus in a safe setting to see if the spray helps control your asthma.
Hear when a new Staphylococcus Aureus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.